Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
Loading...
Embargo End Date
ICR Authors
Authors
Maio, M
Hamid, O
Larkin, J
Covre, A
Altomonte, M
Calabrò, L
Vardhana, SA
Robert, C
Ibrahim, R
Anichini, A
Wolchok, JD
Giacomo, AMD
Hamid, O
Larkin, J
Covre, A
Altomonte, M
Calabrò, L
Vardhana, SA
Robert, C
Ibrahim, R
Anichini, A
Wolchok, JD
Giacomo, AMD
Document Type
Journal Article
Date
2020-08-15
Date Accepted
2020-06-09
Abstract
The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic.
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 26 (16), pp. 4201 - 4205
Source Title
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
1078-0432
eISSN
1557-3265
Collections
Research Team
Melanoma and Kidney Cancer